In the past three years, Dova Pharmaceuticals has completed a company launch, gone public, and won its first drug approval. Now the biotech is in line to be acquired by Swedish Orphan Biovitrum (Sobi).
According to deal terms announced Monday, Dova (NASDAQ: DOVA) stockholders will receive $27.50 per share up front, a 36 percent premium over the company’s closing price on Friday. Sobi would also pay shareholders of Durham, NC-based Dova $1.50 more per share if the company’s FDA-approved drug blood disorder drug gets the regulatory nod as a treatment for an additional population of patients. That would bring deal’s… Read more »
UNDERWRITERS AND PARTNERS
